Feline probiotic lactobacilli composition and methods
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A23K-001/00
A23K-001/18
A61K-035/747
C12N-001/20
C12R-001/225
출원번호
US-0443974
(2006-05-31)
등록번호
US-9427000
(2016-08-30)
발명자
/ 주소
Boileau, Thomas William-Maxwell
Kiley, Barry Pius
O'Mahony, Liam Diarmuid
MacSharry, John
Sunvold, Gregory Dean
출원인 / 주소
Mars, Incorporated
대리인 / 주소
Mars, Incorporated
인용정보
피인용 횟수 :
0인용 특허 :
191
초록▼
According to the invention there is provided a strain of lactic acid bacteria of the genus Lactobacilli obtainable by isolation from resected and washed feline gastrointestinal tract having a probiotic activity in animals. Methods of use and compositions comprising the Lactobacilli of the present in
According to the invention there is provided a strain of lactic acid bacteria of the genus Lactobacilli obtainable by isolation from resected and washed feline gastrointestinal tract having a probiotic activity in animals. Methods of use and compositions comprising the Lactobacilli of the present invention are also provided.
대표청구항▼
1. A composition comprising a biologically purified strain of adherent lactic acid bacteria of the genus Lactobacilli isolated from resected and washed feline gastrointestinal tract having probiotic activity, and having the ability to survive and colonize the gastrointestinal tract of a companion an
1. A composition comprising a biologically purified strain of adherent lactic acid bacteria of the genus Lactobacilli isolated from resected and washed feline gastrointestinal tract having probiotic activity, and having the ability to survive and colonize the gastrointestinal tract of a companion animal, wherein said strain is selected from the group consisting of Lactobacillus salivarius ss salicinius NCIMB 41287 (AHF 122A), Lactobacillus animalis NCIMB 41288 (AHF 223C), and Lactobacillus reuteri NCIMB 41289 (AHF 5119) and a carrier. 2. The composition according to claim 1, said strain having at least 33% growth when cultured in the presence of 0.5% feline bile salts. 3. The composition according to claim 1, wherein the strain of adherent lactic acid bacteria is able to maintain viability following 1 hour at pH 2.5. 4. The composition according to claim 1, wherein the lactic acid bacterial strain has a 16s-23s spacer region DNA sequence selected from SEQ. ID NO. 1, SEQ. ID NO. 2, or SEQ. ID NO. 3. 5. The composition according to claim 1, wherein the companion animal is a cat. 6. The composition according to claim 1, wherein said composition is in a form selected from the group consisting of a companion animal food, kibbles, chews, a supplement, a gravy, yoghurt, cheese, dairy produce, capsules, tablets, pills, and combinations thereof. 7. The composition according to claim 6, wherein the companion animal food is a cat food. 8. The composition according to claim 6, wherein the companion animal food is selected from the group consisting of a wet animal food and a dry animal food. 9. A method of maintaining or improving the health of a companion animal comprising orally administering a composition comprising a biologically purified strain of adherent lactic acid bacteria of the genus Lactobacilli isolated from resected and washed feline gastrointestinal tract having probiotic activity, and having the ability to survive and colonize the gastrointestinal tract of a companion animal, wherein said strain is selected from the group consisting of Lactobacillus salivarius ss salicinius NCIMB 41287 (AHF 122A), Lactobacillus animalis NCIMB 41288 (AHF 223C), and Lactobacillus reuteri NCIMB 41289 (AHF 5119) and a carrier. 10. The method according to claim 9, wherein the strain has at least 33% growth when cultured in the presence of 0.5% feline bile salts. 11. The method according to claim 9, wherein the strain is able to maintain viability following 1 hour at pH 2.5. 12. The method according to claim 9, wherein the lactic acid bacterial strain has a 16s-23s spacer region DNA sequence having greater than 94% homology to SEQ. ID NO. 1, greater than 93% homology to SEQ. ID NO. 2, or greater than 98% homology to SEQ. ID NO. 3. 13. The method according to claim 9, wherein the lactic acid bacterial strain has a 16s-23s spacer region DNA sequence selected from SEQ. ID NO. 1, SEQ. ID NO. 2, or SEQ. ID NO. 3. 14. The method according to claim 9, for the regulation of or improvement of the immune system of a companion animal. 15. The method according to claim 14, for treating autoimmune disease in a companion animal. 16. The method according to claim 14, for treating inflammation in a companion animal. 17. The method according to claim 9, for maintaining or improving the health of the skin and/or coat system of a companion animal. 18. The method according to claim 17, for treating atopic disease of the skin of a companion animal. 19. The method according to claim 9, for ameliorating or reducing the effects of aging in a companion animal. 20. The method according to claim 9, for treating weight loss during and following infection in a companion animal. 21. The method according to claim 9, for treating gastrointestinal infection in a companion animal. 22. The method according to claim 21, for improving microbial ecology of a companion animal. 23. The method according to claim 22, comprising reducing the levels of pathogenic bacteria in the faeces of a companion animal. 24. The method according to claim 23, wherein said pathogenic bacteria are selected from the group consisting of Clostridia, Escherichia, Salmonella, and mixtures thereof. 25. The method according to claim 9, for treating an urinary tract ailment in a companion animal. 26. The method according to claim 25, wherein said urinary tract ailment comprises urinary tract infection. 27. The method according to claim 25, wherein said urinary tract ailment comprises urinary tract stones. 28. The method according to claim 9, for increasing fiber digestion in a companion animal. 29. The method according to claim 9, for reducing stress levels in a companion animal. 30. The method according to claim 29, wherein said stress levels are measured by determining the level of stress hormones selected from the group consisting of epinephrine, norepinephrine, dopamine, cortisol, C-reactive protein and mixtures thereof. 31. The method according to claim 9, wherein the strain is fed to a companion animal in any amount from 1.0E+04 to 1.0E+12 CFU/animal per day. 32. The method according to claim 9, wherein the companion animal is a cat. 33. A method of reducing odor associated with the feces or urine of a companion animal comprising orally administering a composition comprising a biologically purified strain of adherent lactic acid bacteria of the genus Lactobacilli isolated from resected and washed feline gastrointestinal tract, having probiotic activity, and having the ability to survive and colonize the gastrointestinal tract of a companion animal, wherein said strain is selected from the group consisting of Lactobacillus salivarius ss salicinius NCIMB 41287 (AHF 122A), Lactobacillus animalis NCIMB 41288 (AHF 223C), and Lactobacillus reuteri NCIMB 41289 (AHF 5119), and a carrier. 34. A method of reducing odor associated with a litter box of a companion animal comprising orally administering a composition comprising a biologically purified strain of adherent lactic acid bacteria of the genus Lactobacilli isolated from resected and washed feline gastrointestinal tract, having probiotic activity, and having the ability to survive and colonize the gastrointestinal tract of a companion animal, wherein said strain is selected from the group consisting of Lactobacillus salivarius ss salicinius NCIMB 41287 (AHF 122A), Lactobacillus animalis NCIMB 41288 (AHF 223C), and Lactobacillus reuteri NCIMB 41289 (AHF 5119), and a carrier. 35. The method according to claim 34, wherein said composition is in a form selected from the group consisting of a companion animal food, kibbles, chews, a supplement, a gravy, yoghurt, cheese, dairy produce, capsules, tablets, pills, and combinations thereof.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (191)
Bengs,Holger; Brunner,Anette, α-Amylase-resistant starch for producing foodstuff and medicaments.
Leer, Robert Jan; Pouwels, Pieter Hendrik; Conway, Patricia Lynne, ADHERENCE FACTORS OF NON PATHOGENIC MICROORGANISMS AND APPLICATIONS THEREOF FOR SCREENING MICROORGANISMS FOR SPECIFIC PROBIOTIC PROPERTIES; NOVEL PHARMACEUTICAL COMPOSITIONS AND FOOD ADDITIVES COMPRI.
Leonard Walter G. (1017 Main St. Melrose MA 02176) Doble ; Jr. Henry P. (Sunnyview Dr. Redding CT 06875) Nuckols Walter S. (119 Putnam Park Rd. Bethel CT 06801), Calendar-oriented pill dispenser.
Boileau, Thomas William-Maxwell; Ceddia, Michael Anthony; Collins, John Kevin; Davenport, Gary Mitchell; Kiely, Barry Pius; O'Mahony, Liam Diarmuid; Sunvold, Gregory Dean; Tetrick, Mark Alan; Vickers, Robert Jason, Canine probiotic .
Henderson, Todd R.; Lippiello, Louis; Filburn, Charles; Griffin, David, Combination of unsaponifiable lipids combined with polyphenols and/or catechins for the protection, treatment and repair of cartilage in joints of humans and animals.
Rochat, Florence; Schiffrin, Eduardo; Guigoz, Yves, Composition comprising a prebiotic for decreasing inflammatory process and abnormal activation of non-specific immune parameters.
Marttila Esko (Perttula FIX) Larma Ilkka (Espoo FIX) Vahervuo Kari (Espoo FIX) Uotila Jaakko (Espoo FIX), Composition for the oral administration of pharmaceuticals.
Sinclair, David A.; Howitz, Konrad T.; Zipkin, Robert E.; Bitterman, Kevin J.; Lamming, Dudley W., Compositions for manipulating the lifespan and stress response of cells and organisms.
Lamothe Jean-Pierre H. G. (Toulouse FRX) Marchenay Yves G. (Boulogne FRX) Monsan Pierre F. (Blagnac FRX) Paul Francois M. B. (Toulouse FRX) Pelenc Vincent (Toulouse FRX), Cosmetic compositions containing oligosaccharides.
Reddy Malireddy S. (6983 S. Telluride St. Aurora CO 80016), Enhancement of lactobacillus acidophilus growth and viability in yogurt and other cultured dairy products.
Collings George F. (Auburn KS) Stout Neil P. (Topeka KS) Cowell Christopher S. (Topeka KS) Plas Stephen J. (Topeka KS), Extruded dog treat food product having improved resistance to breakage.
Reid Gregor (London CAX) Bruce Andrew W. (Toronto CAX), Lactobacillus and skim milk compositions and methods for preventing microbial urogenital infections.
Vidal, Karine; Donnet-Hughes, Anne; Granato, Dominique-Anne; Corthesy-Theulaz, Irene, Lipoteichoic acid from lactic acid bacteria and its use to modulate immune responses mediated by gram-negative bacteria, potential pathogenic gram-positive bacteria.
Piccirilli, Antoine; Piccardi, Nathalie; Msika, Philippe; Paul, François; Bredif, Stéphanie, Medicament comprising a peptide extract of avocado, which is intended for the treatment and prevention of illnesses that are linked to an immune system deficiency.
Piccirilli, Antoine; Piccardi, Nathalie; Msika, Philippe; Paul, François; Bredif, Stéphanie, Medicament comprising a peptide extract of avocado, which is intended for the treatment and prevention of illnesses that are linked to an immune system deficiency.
Piccirilli, Antoine; Piccardi, Nathalie; Msika, Philippe; Paul, François; Bredif, Stéphanie, Medicament comprising a peptide extract of avocado, which is intended for the treatment and prevention of illnesses that are linked to an immune system deficiency or oxidative stress or skin ageing or dry skin.
Nahill Edmond P. (56 Pleasant St. Methuen MA 01844) Nahill James C. (9 Sunset Ave. Methuen MA 01844) Nahill William A. (10 Glen Ave. Methuen MA 01844) Nahill Arthur (51 East St. Methuen MA 01844), Medicine dispensing system.
Pitha, Josef; Roth, George S; Hayek, Michael Griffin; Massimino, Stefan Patrick; Ceddia, Michael Anthony; Davenport, Gary Mitchell; Burr, John Russell, Method of maintaining and/or attenuating a decline in quality of life.
Boileau, Thomas William-Maxwell; Ceddia, Michael Anthony; Collins, John Kevin; Davenport, Gary Mitchell; Kiely, Barry Pius; O'Mahony, Liam Diarmuid; Sunvold, Gregory Dean; Tetrick, Mark Alan; Vickers, Robert Jason, Method of treating diarrhea in a canine.
Chen, Hao; Liu, Ming; Sathyamoorthy, Malathi; Su, Qi; Leary, Lisa; Zhong, Wayne Shaobin, Method of using dopamine reuptake inhibitors and their analogs for treating diabetes symptoms and delaying or preventing diabetes-associated pathologic conditions.
Boileau, Thomas William-Maxwell; Ceddia, Michael Anthony; Davenport, Gary Mitchell; Kiely, Barry Pius; O'Mahony, Liam Diarmuid; Sunvold, Gregory Dean; Tetrick, Mark Alan; Vickers, Robert Jason, Methods of use of probiotic Lactobacilli for companion animals.
Boileau, Thomas William-Maxwell; Ceddia, Michael Anthony; Davenport, Gary Mitchell; Kiely, Barry Pius; O'Mahony, Liam Diarmuid; Sunvold, Gregory Dean; Tetrick, Mark Alan; Vickers, Robert Jason, Methods of use of probiotic for companion animals.
Sozzi Tomaso (Lausanne CHX) Schrenk Alfred (Orbe CHX) Buhler Marcel (Tolochenaz CHX), Microcapsule containing a microorganism and a process for its production.
Stern Norman J. (Athens GA) Bailey J. Stan (Athens GA) Cox ; Jr. Nelson A. (Athens GA) Blankenship Leroy C. (Athens GA), Nucosal competitive exclusion flora.
Garcia-Rodenas, Clara Lucia; Bergonzelli, Gabriela; Rochat, Florence; Turini, Marco Enrico; Corthesy-Theulaz, Irène; Cherbut, Christine, Nutritional formula for optimal gut barrier function.
Dittmar, Gregory Paul; Amante, Joseph Michael; Cronk, Tony Ryan; Newby, Daniel Gary, Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures.
Grahn Eva E. (Bondegatan 32 UmeS-902 54 SEX) Holm Stig E. F. (Gimonsvgen 25 UmeS-902 40 SEX), Pharmaceutical preparation for controlling pathogenic intestinal bacteria.
Hatano Harumi,JPX ; Ito Takahiro,JPX ; Ishibashi Takashi,JPX ; Yoshino Hiroyuki,JPX ; Mizobe Masakazu,JPX, Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract.
Ikushima Heiji (Saitama-ken JPX), Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the int.
Plail, Regina; Schatzmayr, Gerd; Binder, Eva Maria; Mohnl, Michaela; Klimitsch, Alfred; Nitsch, Sabine; Klose, Viviana, Probiotic health or fitness promoting human or animal foodstuff and/or drinking water additive and use thereof.
Rutherford William M. (Des Moines IA) Allen Jack E. (Boonville IA) Schlameus Herman W. (San Antonio TX) Mangold Donald J. (San Antonio TX) Harlowe ; Jr. William W. (San Antonio TX) Lebeda Joseph R. (, Process for preparing rotary disc fatty acid microspheres of microorganisms.
Reimann Josef (Kirchlintein-Hohenaverbergen DEX) Sirel Tas (Verden-Walle DEX) Steinberg Eckhart (Verden DEX) Hornig Rolf (Kirchlintein-Luttum DEX) Czempik Klaus (Minden DEX) Khler Friedrich (Martfeld, Process for the production of a lumpy meat emulsion product.
Miller James G. (Ellicott City MD) Wax Michael J. (Bethesda MD) Wormsbecher Richard F. (Highland MD) Aller Leo B. (Severna Park MD) Durham Donald R. (Gaithersburg MD) Chmurny Alan B. (Frederick MD), Process upset-resistant inorganic supports for bioremediation.
Shenouda Soliman (Tarrytown NY) Clausi Adolph (Cos Cob CT) Rogers Ann M. (Rivervale NJ) El-Hag Nabil (Putnam Valley NY), Reduction of microbial population on surface of food materials.
Reddy Malireddy S. (6983 S. Telluride St. Aurora CO 80016), Shelf life and subsequent growth of lactobacillus acidophilus, propionibacterium shermanii and leuconos.
DeNeale Richard J. (Morrisonville NY) Guley Paul C. (Plattsburgh NY) Milosovich George (Rouses Point NY), Sustained release pharmaceutical compositions.
Friedman Mark I. (Merion PA) Tordoff Michael G. (Philadelphia PA) DiNovi Michael J. (Philadelphia PA) Rafka Robert J. (Ardmore PA), Use of 2,5-anhydro-D-mannitol as a food intake modifier.
De Simone, Claudio, Use of bacteria endowed with arginine deiminase to induce apoptosis and/or reduce an inflammatory reaction and pharmaceutical or dietetic compositions containing such bacteria.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.